Gilead Sciences, Inc. (NASDAQ:GILD) Baird 2022 Global Healthcare Conference September 14, 2022 9:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney Good morning, everyone. Thank you for joining us our next fireside chat. I'm really pleased to have with me the Chief Commercial Officer of Gilead Sciences, Johanna Mercier. Gilead is a name I'm sure everyone is familiar with. It's one of the bellwethers of the sector, a long- ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:35 AM ET Company Participants Daniel O'Day - Chairman & CEO William Grossman - SVP, Oncology Clinical Development Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison I think we're ready. So good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Gilead with u ...

Gilead Sciences, Inc. (NASDAQ:GILD) 2022 Wells Fargo Healthcare Conference September 8, 2022 10:25 AM ET Company Participants Andrew Dickinson - CFO Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great. Thank you very much for this session. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo. And with us, we have Andy, the CFO of Gilead. Thank you very much, Andy, for joining us. Andrew Dickinson Thank you for having us. Happy to be here. Question-and-Answer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ...

Gilead Science's second quarter 2022 earnings conference call. All lines have been placed on mute to prevent background noises. After today's remarks, there will be a question and answer session. If you would like to ask a question, please press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star followed by two. Please be advised that today's call is being recorded. I would now like to hand the conference over to Jackie Ross Vice President of In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ t ...

The End Thank you for standing by, and welcome to the Gilead Scientists First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. Please be advised that today's call is being recorded. If you require any further assistance, please press star 0. I would now like to hand the call over to your host for t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdiction of I ...